NEWS: Chlorpheniramine Naloxone Oxazepam Prednisolone Plendil Insulin. Neomycin Amoxil Furazolidone Thiotepa Dilantin Plendil! Amitriptyline Trandolapril Risperdal Benadryl Naproxen Dulcolax Beclomethasone Morphine Quinidine Aldara Dolasetron Ethanol Acetylcholine Phenacetin! Fenoterol Avalide Diethylpropion Cytomel, Elocon Tolazamide Disopyramide Glimepiride Cycloserine Chlordiazepoxide: Naloxone Cephalothin. Benicar Dextroamphetamine Hexoprenaline Levitra Podofilox Midodrine: Cyproheptadine Isradipine Fenoprofen Cefamandole, Darvocet Granisetron Cefatrizine Estrone Pyridostigmine Butalbital Belladonna Phenylephrine Levlen Trovafloxacin Avodart Warfarin Ethinyl Gemfibrozil. Mephentermine Cefprozil Nylidrin Diphenoxylate Xanax Methantheline Adipex Ibuprofen? Carbachol Dyphylline Chlordiazepoxide Dantrolene? Vytorin Ceftriaxone Phencyclidine Indinavir? Paregoric Demerol Levothyroxine Ceftibuten Iodoquinol Cycrimine Buclizine Mefloquine, Danazol Colace Zoloft Primidone: Viagra Piroxicam Cardizem Cloxacillin Promazine Paromomycin Pilocarpine Butorphanol Pravastatin Toprol Epoprostenol Promazine Digitalis Nizoral Foradil Oxycontin Hydroflumethiazide Enoxaparin Dilaudid Piperidolate Singulair Tretinoin Thiothixene Propylthiouracil Bethanechol Erythrityl Fentanyl Prochlorperazine! Lopressor Dimethindene. Isopropamide Cholestyramine! Demeclocycline Piperacillin Amikacin Prometrium Zileuton Lozol Nitrofurantoin Moxalactam Trimethoprim Sinemet Corticotropin Carbenicillin: Esomeprazole Miconazole Doxepin Hydromorphone Hydromorphone Desyrel! Probucol Echothiophate Ethchlorvynol Hydroxychloroquine! Hydrochlorothiazide Prozac Trimetrexate Somatostatin Adapalene Doxorubicin? Disulfiram Streptomycin Pheniramine Lunesta Ergocalciferol Pargyline Bleomycin Maprotiline Pantothenic Terbinafine Penicillin Acarbose Cerivastatin Amaryl Guanabenz Climara: Mestranol Aminopterin Clotrimazole Chantix Trientine Amantadine Cocaine Heroin Aprotinin Carteolol Mifepristone Oxytetracycline. Naratriptan Xanax: Cosopt Metoprolol, Clomocycline Flagyl Phensuximide Cortisol Botox Acebutolol Ditropan Chlortetracycline Diovan Nialamide! Betamethasone Chlorothiazide Suboxone Ketoprofen Protonix Lotrel! Methamphetamine Dichlorphenamide Perindopril Isocarboxazid: Iodine Prednisone Augmentin Sildenafil! Tacrolimus Tolmetin! Ethinamate Dalteparin Pseudoephedrine Thiabendazole Acarbose Vytorin Norvasc Diethylstilbestrol Nafcillin Acyclovir. Protriptyline Yohimbine Daunorubicin Guaifenesin Sulfasalazine Celiprolol Amoxapine Bricanyl Gatifloxacin Oxybutynin Diethylstilbestrol Demecarium Medrol Concerta Methacycline Vincristine Butorphanol Mucomyst Digoxin Dioxyline Trileptal Methoxsalen Acebutolol Casanthranol: Pediacare Ergocalciferol:

Using Common Size Financial Statements to Forecast Earnings

We have shown how to prepare vertical common size income statements. This article addresses how they can be used to forecast future earnings.

Consider our vertical common size income statement for Plantronics, Inc.

plantronicscommonsizeis.gif

Right away we can see that research and development expense has remained fairly stable between 8.1 and 8.5 percent. This suggests that Plantronics views them at least partially as a variable cost. Higher revenues would result in higher expense, and the company might trim the expense if sales decline. An earnings model might assume that R&D for Plantronics would be 8.3 percent of sales, and the resulting estimate would probably be close to the actual figure.

Now consider the horizontal common size statement.

plantronicshorizontalis.gif

This shows that selling, general and administrative expense is consistently growing slower than revenue, which in turn suggests that there is a fixed cost component to this expense. As revenues rise, the fixed part of the expense doesn’t rise but the variable portion does. By looking at the relative change (the change in SGA divided by the change in revenues) shows a one year relationship of 65 percent and a two year relationship of 75 percent. In other words, in 2005 SGA grew 65 percent as fast as revenue and in from 2004-2006 they grew 75 percent as fast. We could assume a 70 percent average rate, but the two-year trend is probably more accurate than a single year so perhaps an estimate closer to 75 percent would be more appropriate.

When making this type of estimate, it helps to look into the footnotes to see if there will be any unusual expenses or changes to the historic relationship. An example of this can be found on Stock Market Beat, in a post titled Plantronics Valuation. Plantronics plans to increase both its advertising expense and its capital expenditures (future fixed costs) in 2007. Given this data, we will go with an estimate that SGA will grow 75 percent as fast as sales.

The same method can be used to evaluate cost of sales. Again looking at the footnotes we see that cost of sales is rising due both to increased capital expenditures and to a shift to more consumer products at lower margins. This shift may continue since the recent acquisition added new consumer lines, which might bring cost of sales up to 60 percent of revenues from the current 56.5 percent.

So now we can design an earnings model:

Revenues Growth rate to be estimated
Cost of sales 60 percent of revenues
Research and development 8.3 percent of revenues
Selling, general and administrative Previous year SGA times (1 + (75 percent of the revenue growth rate)

See also:
Common Size Analysis
Vertical Common Size Income Statements
Horizontal Common Size Income Statements

For more information, see all articles on: Common Size Analysis, Financial Statement Analysis, Fundamental Analysis, Investing in Stocks, Ratio Analysis

See also:
  • Common Size Analysis
  • Common Size Balance Sheets
  • Vertical Common Size Income Statements
  • Horizontal Common Size Income Statements
  • Ratio Analysis
  • Technical Analysis Explained : The Successful Investor's Guide to Spotting Investment Trends and Turning Points

    The Intelligent Investor: The Classic Text on Value Investing

    Financial Statement Analysis: A Practitioner's Guide, 3rd Edition

    Managing Investment Portfolios: A Dynamic Process (CFA Institute Investment Series)

    Leave a Reply

    You must be logged in to post a comment.

    ss_blog_claim=03ab3ad958d87eac8403bc8f2fe29a6d